DexCom, Inc. is a medical technology company focused on developing and marketing continuous glucose monitoring (CGM) systems for diabetes management. Its product portfolio includes devices like the Dexcom G6 and G7, which provide real-time glucose data, and supplementary services such as Dexcom Share and an API for digital health application integration. The company aims to broaden access to glucose monitoring through offerings like Dexcom ONE and Stelo. In terms of recent quarterly performance, DexCom reported Q4 2025 actual EPS of $0.68, significantly beating the estimate of $0.48, with revenue at $1.26 billion against an estimate of $1.18 billion. This followed a Q3 2025 where actual EPS of $0.61 surpassed the estimate of $0.57, and revenue was $1.21 billion. Prior to this, Q2 2025 saw actual EPS of $0.48 exceed the estimate of $0.44, with revenue at $1.16 billion, and Q1 2025 reported actual EPS of $0.32 against an estimate of $0.33, with revenue at $1.04 billion. The trend indicates a strong acceleration in EPS beats and revenue growth in the latter half of 2025 after a slight miss in Q1 2025. Historically, DexCom has demonstrated a consistent upward trajectory in year-over-year growth, with a strong pattern of beating analyst estimates for both EPS and revenue in recent quarters, particularly in the latter half of 2025. The company has shown a robust ability to exceed expectations, highlighting effective product adoption and market penetration. Recent news indicates that DexCom shares have outperformed competitors, suggesting positive market sentiment, although the stock has also experienced recent price weakness over the past month, prompting a reassessment of its intrinsic value. The company has scheduled its Q1 2026 earnings release for April 30, 2026. Investors will be watching for continued strong performance in its latest CGM devices and any updates on product development and market expansion. Key will be the company's ability to sustain its recent trend of significant EPS beats and revenue growth, as well as how it navigates any ongoing price weakness and competitive pressures in the diabetes technology market.
